LONDON – Six weeks after divesting its portfolio of marketed cancer drugs, Glaxosmithkline (GSK) plc is stepping up investment in oncology R&D, in a $350 million deal with T-cell immunotherapy specialist, Adaptimmune Ltd., for its lead program NY-ESO-1.
